70
Advanced Library Amplifi cation Mix Enhances NGS Data Quality
PCR Biosystems has launched VeriFi™ Library Amplification Mix, a proofreading polymerase mix that reduces GC-dependent bias in NGS library preparation workflows. The mix is designed to guarantee high-quality sequencing results for long and complex targets, enabling researchers to acquire superior sequencing datasets with a higher number of unique reads.
VeriFi™ Library Amplification Mix combines VeriFi™ Hot Start Polymerase with proprietary chemistry to minimise GC-bias and utilises AptaLock™ hot start technology to ensure reliable amplification. The mix has undergone rigorous testing on Illumina platforms and has been shown to have minimal bias, even during amplification at extremes of GC content ranging from 30.
In an external, blind experiment with three market-leading competitors, the researcher running the study picked VeriFi™ Library Amplification Mix as the best performing and reported detecting 2%
more unique reads, which leads to greater target sequence coverage and more accurate quantitative information. VeriFi™ Library Amplification Mix is easy to use with its 2x mix format, which simplifies the workflow and improves reproducibility.
Alex Wilson, Co-founder and Business Development Manager, PCR Biosystems stated: “Empowering researchers to advance their research and unlock new insights is the driving force behind everything we do at PCR Biosystems. We are proud that we have developed this cutting- edge mix, which is cost-effective and will truly benefit researchers, giving them more and better data when undertaking costly and laborious NGS experiments.”
More information online:
ilmt.co/PL/w1kR 60231pr@reply-direct.com
New Reagent Solution for Immunohistochemistry Aptamer Group plc, a company that specialises in developing Optimer®
life sciences industry, has announced the creation of a new reagent, Optimer® designed for use in automated immunohistochemistry (IHC) workfl ows.
binders for the -Fc, which is
Optimer-Fc combines an Optimer binder with the Fc domain of an antibody, making it an alternative to primary detecting antibodies in IHC applications. With the broad range of target options available, the Optimer-Fc can be used to pursue both existing and novel disease biomarkers, providing greater accuracy and selectivity in detection.
IHC is currently the gold standard test for clinical diagnostics, including cancer, and is increasingly being used with personalised medicine approaches. However, the major players in the IHC fi eld are facing a signifi cant challenge due to the imminent expiry of current patents for IHC antibodies, leading to an expected decrease in revenue and profi tability. Aptamer’s innovative Optimer-Fc reagent addresses this issue and is being validated by one of the top three companies in the IHC market, with negotiations underway with two top 10 pharmaceutical companies seeking to trial Optimer-Fc.
Aptamer is also collaborating with four of the top ten pharma companies and additional biotech partners to develop Optimer binders for IHC, creating a deep pipeline of potential future products to advance research and diagnostics in the life sciences industry. Dr Arron Tolley, Aptamer’s CEO, notes that Optimer-Fc addresses an urgent need in the IHC market for new patentable reagents and provides the ability to pursue new targets that were previously intractable with antibodies, opening up further opportunities for emerging biomarkers in research and diagnostics.
More information online:
ilmt.co/PL/5q8Z 60232pr@reply-direct.com
What’s in the next issue? Find out with a copy of our Media Information Pack.
Contact our sales team for your copy.
sales@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
